Human Primary Cell Market By Type (Blood (peripheral) cells, Endothelial cells, Epithelial cells, Fibroblast cells, Hepatocyte cells, Keratinocyte cells, Melanocyte cells, Pancreatic cells, Smooth muscle cells, Skeletal cells, Adipocyte cells); By Application (Pharmaceutical, Biotechnology, Cosmetics, Academia); By Geography (North America, Europe, China, Japan, South-East Asia, India) ¬- Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018 - 2026

Report ID :AMI-154 | Category : Life Science | Published Date : December, 2018 | Pages : 285 | Format :PDF

Industry Trends

Human Primary cells are isolated from human tissues via enzymatic or mechanical method. These cells provide infrangible and usual experimental outcomes, as they are physiologically normal. Normal primary cells preserve almost all native cellular functions in vitro, such as morphology, growth characteristics, cellular makers, signaling and genetic integrity. Companies offering human primary cells are required to comply with ethical sourcing and related regulations prevalent in their operating regions.

Increasing usage of these primary cells in medical and clinical research, for the study of cell structure & functions and for drug development is positively impacting the Human Primary Cell Market  growth. These cells have vital importance in areas such as cancer research, and studies related to various other chronic diseases. Moreover, cells such as fibroblasts, keratinocytes and Melanocytes are also used in the cosmetics industry for the testing for various cosmetic products. The developed regions are presently bigger markets for human primary cells with their exorbitantly high investments in medical research field. The demand in emerging economies is comparatively lesser, however, is expected to witness a notable growth in near future.

Human Primary Cell Market is expected to grow with a CAGR of 7% during the forecast period of 2017-2026. The study analyzes the market in terms of revenue and sales volume across all the major markets.

Asia Pacific, Human Primary Cell Sales, 2017 - 2026

Human Primary Cell Market

Competitive Landscape

The report provides both, qualitative and quantitative research of the market, as well as provides worthy insights into the rational scenario and favored development methods adopted by the key contenders. The Human Primary Cell Market report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their headquarter, competitors, product type, application and specification, pricing, and gross margin.

Some of the players operating in the human primary cell market are Lonza, Thermo Fisher Scientific, Sigma-Aldrich, Cell Biologics, PromoCell GmbH, Cureline, Zen-Bio, Stemcell Technologies, Pelobiotech, among the others.

By Type 

  • Blood (peripheral) cells
  • Endothelial cells
  • Epithelial cells
  • Fibroblast cells
  • Hepatocyte cells
  • Keratinocyte cells
  • Melanocyte cells
  • Pancreatic cells
  • Smooth muscle cells
  • Skeletal cells
  • Adipocyte cells

By Application

  • Pharmaceutical
  • Biotechnology
  • Cosmetics
  • Academia

By Geography

  • North America
    • U.S.
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Middle East and Africa
    • GCC Countries
    • Southern Africa
    • Rest of Middle East and Africa
  • Latin America
    • Brazil
    • Rest of Latin America

1.    Introduction

1.1.  Market Scope

1.2.  Market Segmentation

1.3.  Methodology

1.4.  Assumptions

2.    Human Primary Cell Market Snapshot

3.    Executive Summary: Human Primary Cell Market

4.    Qualitative Analysis: Human Primary Cell Market

4.1.   Introduction

4.1.1. Product Definition

4.1.2. Industry Development

4.2.   Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Opportunities

4.3.   Trends in Human Primary Cell Market

5.    Global Human Primary Cell Market Analysis and Forecasts, 2018 – 2026

5.1.   Overview

5.1.1.   Global Human Primary Cell Market Revenue (US$ Mn) and Forecasts

5.2.   Global Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

5.2.1.   Blood (peripheral) cells

5.2.1.1.  Definition

5.2.1.2.  Market Penetration

5.2.1.3.  Market Revenue Expected to Increase by 2026

5.2.1.4.  Compound Annual Growth Rate (CAGR)

5.2.2.   Endothelial cells

5.2.2.1.  Definition

5.2.2.2.  Market Penetration

5.2.2.3.  Market Revenue Expected to Increase by 2026

5.2.2.4.  Compound Annual Growth Rate (CAGR)

5.2.3.   Epithelial cells

5.2.3.1.  Definition

5.2.3.2.  Market Penetration

5.2.3.3.  Market Revenue Expected to Increase by 2026

5.2.3.4.  Compound Annual Growth Rate (CAGR)

5.2.4.   Fibroblast cells

5.2.4.1.  Definition

5.2.4.2.  Market Penetration

5.2.4.3.  Market Revenue Expected to Increase by 2026

5.2.4.4.  Compound Annual Growth Rate (CAGR)

5.2.5.   Hepatocyte cells

5.2.5.1.  Definition

5.2.5.2.  Market Penetration

5.2.5.3.  Market Revenue Expected to Increase by 2026

5.2.5.4.  Compound Annual Growth Rate (CAGR)

5.2.6.   Keratinocyte cells

5.2.6.1.  Definition

5.2.6.2.  Market Penetration

5.2.6.3.  Market Revenue Expected to Increase by 2026

5.2.6.4.  Compound Annual Growth Rate (CAGR)

5.2.7.   Melanocyte cells

5.2.7.1.  Definition

5.2.7.2.  Market Penetration

5.2.7.3.  Market Revenue Expected to Increase by 2026

5.2.7.4.  Compound Annual Growth Rate (CAGR)

5.2.8.   Pancreatic cells

5.2.8.1.  Definition

5.2.8.2.  Market Penetration

5.2.8.3.  Market Revenue Expected to Increase by 2026

5.2.8.4.  Compound Annual Growth Rate (CAGR)

5.2.9.   Smooth muscle cells

5.2.9.1.  Definition

5.2.9.2.  Market Penetration

5.2.9.3.  Market Revenue Expected to Increase by 2026

5.2.9.4.  Compound Annual Growth Rate (CAGR)

5.2.10. Skeletal cells

5.2.10.1.  Definition

5.2.10.2.  Market Penetration

5.2.10.3.  Market Revenue Expected to Increase by 2026

5.2.10.4.  Compound Annual Growth Rate (CAGR)

5.2.11. Adipocyte cells

5.2.11.1.  Definition

5.2.11.2.  Market Penetration

5.2.11.3.  Market Revenue Expected to Increase by 2026

5.2.11.4.  Compound Annual Growth Rate (CAGR)

5.3.   Key Segment for Channeling Investments

5.3.1. By Type

6.    Global Human Primary Cell Market Analysis and Forecasts, 2018 – 2026

6.1.   Overview

6.2.   Global Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

6.2.1.   Pharmaceutical

6.2.1.1.  Definition

6.2.1.2.  Market Penetration

6.2.1.3.  Market Revenue Expected to Increase by 2026

6.2.1.4.  Compound Annual Growth Rate (CAGR)

6.2.2.   Biotechnology

6.2.2.1.  Definition

6.2.2.2.  Market Penetration

6.2.2.3.  Market Revenue Expected to Increase by 2026

6.2.2.4.  Compound Annual Growth Rate (CAGR)

6.2.3.   Cosmetics

6.2.3.1.  Definition

6.2.3.2.  Market Penetration

6.2.3.3.  Market Revenue Expected to Increase by 2026

6.2.3.4.  Compound Annual Growth Rate (CAGR)

6.2.4.   Academia

6.2.4.1.  Definition

6.2.4.2.  Market Penetration

6.2.4.3.  Market Revenue Expected to Increase by 2026

6.2.4.4.  Compound Annual Growth Rate (CAGR)

6.3.   Key Segment for Channeling Investments

6.3.1.   By Application

7.    North America Human Primary Cell Market Analysis and Forecasts, 2018 – 2026

7.1.   Overview

7.1.1. North America Human Primary Cell Market Revenue (US$ Mn)

7.2.   North America Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

7.2.1. Blood (peripheral) cells

7.2.2. Endothelial cells

7.2.3. Epithelial cells

7.2.4. Fibroblast cells

7.2.5. Hepatocyte cells

7.2.6. Keratinocyte cells

7.2.7. Melanocyte cells

7.2.8. Pancreatic cells

7.2.9. Smooth muscle cells

7.2.10. Skeletal cells

7.2.11. Adipocyte cells

7.3.   North America Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

7.3.1. Pharmaceutical

7.3.2. Biotechnology

7.3.3. Cosmetics

7.3.4. Academia

7.4.   North America Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Country

7.4.1.   U.S.

7.4.1.1.    U.S. Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

7.4.1.1.1.   Blood (peripheral) cells

7.4.1.1.2.   Endothelial cells

7.4.1.1.3.   Epithelial cells

7.4.1.1.4.   Fibroblast cells

7.4.1.1.5.   Hepatocyte cells

7.4.1.1.6.   Keratinocyte cells

7.4.1.1.7.   Melanocyte cells

7.4.1.1.8.   Pancreatic cells

7.4.1.1.9.   Smooth muscle cells

7.4.1.1.10.Skeletal cells

7.4.1.1.11.Adipocyte cells

7.4.1.2.    U.S. Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

7.4.1.2.1.   Pharmaceutical

7.4.1.2.2.   Biotechnology

7.4.1.2.3.   Cosmetics

7.4.1.2.4.   Academia

7.4.2.   Rest of North America

7.4.2.1.    Rest of North America Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

7.4.2.1.1.   Blood (peripheral) cells

7.4.2.1.2.   Endothelial cells

7.4.2.1.3.   Epithelial cells

7.4.2.1.4.   Fibroblast cells

7.4.2.1.5.   Hepatocyte cells

7.4.2.1.6.   Keratinocyte cells

7.4.2.1.7.   Melanocyte cells

7.4.2.1.8.   Pancreatic cells

7.4.2.1.9.   Smooth muscle cells

7.4.2.1.10.Skeletal cells

7.4.2.1.11.Adipocyte cells

7.4.2.2.    Rest of North America Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

7.4.2.2.1.   Pharmaceutical

7.4.2.2.2.   Biotechnology

7.4.2.2.3.   Cosmetics

7.4.2.2.4.   Academia

7.5.   Key Segment for Channeling Investments

7.5.1. By Country

7.5.2. By Type

7.5.3. By Application

8.    Europe Human Primary Cell Market Analysis and Forecasts, 2018 – 2026

8.1.   Overview

8.1.1. Europe Human Primary Cell Market Revenue (US$ Mn)

8.2.   Europe Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

8.2.1. Blood (peripheral) cells

8.2.2. Endothelial cells

8.2.3. Epithelial cells

8.2.4. Fibroblast cells

8.2.5. Hepatocyte cells

8.2.6. Keratinocyte cells

8.2.7. Melanocyte cells

8.2.8. Pancreatic cells

8.2.9. Smooth muscle cells

8.2.10. Skeletal cells

8.2.11. Adipocyte cells

8.3.   Europe Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

8.3.1. Pharmaceutical

8.3.2. Biotechnology

8.3.3. Cosmetics

8.3.4. Academia

8.4.   Europe Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Country

8.4.1.   France

8.4.1.1.    France Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

8.4.1.1.1.   Blood (peripheral) cells

8.4.1.1.2.   Endothelial cells

8.4.1.1.3.   Epithelial cells

8.4.1.1.4.   Fibroblast cells

8.4.1.1.5.   Hepatocyte cells

8.4.1.1.6.   Keratinocyte cells

8.4.1.1.7.   Melanocyte cells

8.4.1.1.8.   Pancreatic cells

8.4.1.1.9.   Smooth muscle cells

8.4.1.1.10.Skeletal cells

8.4.1.1.11.Adipocyte cells

8.4.1.2.    France Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

8.4.1.2.1.   Pharmaceutical

8.4.1.2.2.   Biotechnology

8.4.1.2.3.   Cosmetics

8.4.1.2.4.   Academia

8.4.2.   The UK

8.4.2.1.    The UK Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

8.4.2.1.1.   Blood (peripheral) cells

8.4.2.1.2.   Endothelial cells

8.4.2.1.3.   Epithelial cells

8.4.2.1.4.   Fibroblast cells

8.4.2.1.5.   Hepatocyte cells

8.4.2.1.6.   Keratinocyte cells

8.4.2.1.7.   Melanocyte cells

8.4.2.1.8.   Pancreatic cells

8.4.2.1.9.   Smooth muscle cells

8.4.2.1.10.Skeletal cells

8.4.2.1.11.Adipocyte cells

8.4.2.2.    The UK Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

8.4.2.2.1.   Pharmaceutical

8.4.2.2.2.   Biotechnology

8.4.2.2.3.   Cosmetics

8.4.2.2.4.   Academia

8.4.3.   Spain

8.4.3.1.    Spain Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

8.4.3.1.1.   Blood (peripheral) cells

8.4.3.1.2.   Endothelial cells

8.4.3.1.3.   Epithelial cells

8.4.3.1.4.   Fibroblast cells

8.4.3.1.5.   Hepatocyte cells

8.4.3.1.6.   Keratinocyte cells

8.4.3.1.7.   Melanocyte cells

8.4.3.1.8.   Pancreatic cells

8.4.3.1.9.   Smooth muscle cells

8.4.3.1.10.Skeletal cells

8.4.3.1.11.Adipocyte cells

8.4.3.2.    Spain Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

8.4.3.2.1.   Pharmaceutical

8.4.3.2.2.   Biotechnology

8.4.3.2.3.   Cosmetics

8.4.3.2.4.   Academia

8.4.4.   Germany

8.4.4.1.    Germany Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

8.4.4.1.1.   Blood (peripheral) cells

8.4.4.1.2.   Endothelial cells

8.4.4.1.3.   Epithelial cells

8.4.4.1.4.   Fibroblast cells

8.4.4.1.5.   Hepatocyte cells

8.4.4.1.6.   Keratinocyte cells

8.4.4.1.7.   Melanocyte cells

8.4.4.1.8.   Pancreatic cells

8.4.4.1.9.   Smooth muscle cells

8.4.4.1.10.Skeletal cells

8.4.4.1.11.Adipocyte cells

8.4.4.2.    Germany Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

8.4.4.2.1.   Pharmaceutical

8.4.4.2.2.   Biotechnology

8.4.4.2.3.   Cosmetics

8.4.4.2.4.   Academia

8.4.5.   Italy

8.4.5.1.    Italy Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

8.4.5.1.1.   Blood (peripheral) cells

8.4.5.1.2.   Endothelial cells

8.4.5.1.3.   Epithelial cells

8.4.5.1.4.   Fibroblast cells

8.4.5.1.5.   Hepatocyte cells

8.4.5.1.6.   Keratinocyte cells

8.4.5.1.7.   Melanocyte cells

8.4.5.1.8.   Pancreatic cells

8.4.5.1.9.   Smooth muscle cells

8.4.5.1.10.Skeletal cells

8.4.5.1.11.Adipocyte cells

8.4.5.2.    Italy Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

8.4.5.2.1.   Pharmaceutical

8.4.5.2.2.   Biotechnology

8.4.5.2.3.   Cosmetics

8.4.5.2.4.   Academia

8.4.6.   Rest of Europe

8.4.6.1.    Rest of Europe Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

8.4.6.1.1.   Blood (peripheral) cells

8.4.6.1.2.   Endothelial cells

8.4.6.1.3.   Epithelial cells

8.4.6.1.4.   Fibroblast cells

8.4.6.1.5.   Hepatocyte cells

8.4.6.1.6.   Keratinocyte cells

8.4.6.1.7.   Melanocyte cells

8.4.6.1.8.   Pancreatic cells

8.4.6.1.9.   Smooth muscle cells

8.4.6.1.10.Skeletal cells

8.4.6.1.11.Adipocyte cells

8.4.6.2.    Rest of Europe Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

8.4.6.2.1.   Pharmaceutical

8.4.6.2.2.   Biotechnology

8.4.6.2.3.   Cosmetics

8.4.6.2.4.   Academia

8.5.   Key Segment for Channeling Investments

8.5.1. By Country

8.5.2. By Type

8.5.3. By Application

9.    Asia Pacific  Human Primary Cell Market Analysis and Forecasts, 2018 – 2026

9.1.   Overview

9.1.1. Asia Pacific Human Primary Cell Market Revenue (US$ Mn)

9.2.   Asia Pacific Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

9.2.1. Blood (peripheral) cells

9.2.2. Endothelial cells

9.2.3. Epithelial cells

9.2.4. Fibroblast cells

9.2.5. Hepatocyte cells

9.2.6. Keratinocyte cells

9.2.7. Melanocyte cells

9.2.8. Pancreatic cells

9.2.9. Smooth muscle cells

9.2.10. Skeletal cells

9.2.11. Adipocyte cells

9.3.   Asia Pacific Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

9.3.1. Pharmaceutical

9.3.2. Biotechnology

9.3.3. Cosmetics

9.3.4. Academia

9.4.   Asia Pacific Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Country

9.4.1.   China

9.4.1.1.    China Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

9.4.1.1.1.   Blood (peripheral) cells

9.4.1.1.2.   Endothelial cells

9.4.1.1.3.   Epithelial cells

9.4.1.1.4.   Fibroblast cells

9.4.1.1.5.   Hepatocyte cells

9.4.1.1.6.   Keratinocyte cells

9.4.1.1.7.   Melanocyte cells

9.4.1.1.8.   Pancreatic cells

9.4.1.1.9.   Smooth muscle cells

9.4.1.1.10.Skeletal cells

9.4.1.1.11.Adipocyte cells

9.4.1.2.    China Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

9.4.1.2.1.   Pharmaceutical

9.4.1.2.2.   Biotechnology

9.4.1.2.3.   Cosmetics

9.4.1.2.4.   Academia

9.4.2.   Japan

9.4.2.1.    Japan Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

9.4.2.1.1.   Blood (peripheral) cells

9.4.2.1.2.   Endothelial cells

9.4.2.1.3.   Epithelial cells

9.4.2.1.4.   Fibroblast cells

9.4.2.1.5.   Hepatocyte cells

9.4.2.1.6.   Keratinocyte cells

9.4.2.1.7.   Melanocyte cells

9.4.2.1.8.   Pancreatic cells

9.4.2.1.9.   Smooth muscle cells

9.4.2.1.10.Skeletal cells

9.4.2.1.11.Adipocyte cells

9.4.2.2.    Japan Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

9.4.2.2.1.   Pharmaceutical

9.4.2.2.2.   Biotechnology

9.4.2.2.3.   Cosmetics

9.4.2.2.4.   Academia

9.4.3.   India

9.4.3.1.    India Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

9.4.3.1.1.   Blood (peripheral) cells

9.4.3.1.2.   Endothelial cells

9.4.3.1.3.   Epithelial cells

9.4.3.1.4.   Fibroblast cells

9.4.3.1.5.   Hepatocyte cells

9.4.3.1.6.   Keratinocyte cells

9.4.3.1.7.   Melanocyte cells

9.4.3.1.8.   Pancreatic cells

9.4.3.1.9.   Smooth muscle cells

9.4.3.1.10.Skeletal cells

9.4.3.1.11.Adipocyte cells

9.4.3.2.    India Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

9.4.3.2.1.   Pharmaceutical

9.4.3.2.2.   Biotechnology

9.4.3.2.3.   Cosmetics

9.4.3.2.4.   Academia

9.4.4.   Southeast Asia

9.4.4.1.    Southeast Asia Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

9.4.4.1.1.   Blood (peripheral) cells

9.4.4.1.2.   Endothelial cells

9.4.4.1.3.   Epithelial cells

9.4.4.1.4.   Fibroblast cells

9.4.4.1.5.   Hepatocyte cells

9.4.4.1.6.   Keratinocyte cells

9.4.4.1.7.   Melanocyte cells

9.4.4.1.8.   Pancreatic cells

9.4.4.1.9.   Smooth muscle cells

9.4.4.1.10.Skeletal cells

9.4.4.1.11.Adipocyte cells

9.4.4.2.    Southeast Asia Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

9.4.4.2.1.   Pharmaceutical

9.4.4.2.2.   Biotechnology

9.4.4.2.3.   Cosmetics

9.4.4.2.4.   Academia

9.4.5.   Rest of Asia Pacific

9.4.5.1.    Rest of Asia Pacific Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

9.4.5.1.1.   Blood (peripheral) cells

9.4.5.1.2.   Endothelial cells

9.4.5.1.3.   Epithelial cells

9.4.5.1.4.   Fibroblast cells

9.4.5.1.5.   Hepatocyte cells

9.4.5.1.6.   Keratinocyte cells

9.4.5.1.7.   Melanocyte cells

9.4.5.1.8.   Pancreatic cells

9.4.5.1.9.   Smooth muscle cells

9.4.5.1.10.Skeletal cells

9.4.5.1.11.Adipocyte cells

9.4.5.2.    Rest of Asia Pacific Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

9.4.5.2.1.   Pharmaceutical

9.4.5.2.2.   Biotechnology

9.4.5.2.3.   Cosmetics

9.4.5.2.4.   Academia

9.5.   Key Segment for Channeling Investments

9.5.1. By Country

9.5.2. By Type

9.5.3. By Application

10. Middle East and Africa  Human Primary Cell Market Analysis and Forecasts, 2018 – 2026

10.1. Overview

10.1.1. Middle East and Africa Human Primary Cell Market Revenue (US$ Mn)

10.2. Middle East and Africa Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

10.2.1. Blood (peripheral) cells

10.2.2. Endothelial cells

10.2.3. Epithelial cells

10.2.4. Fibroblast cells

10.2.5. Hepatocyte cells

10.2.6. Keratinocyte cells

10.2.7. Melanocyte cells

10.2.8. Pancreatic cells

10.2.9. Smooth muscle cells

10.2.10.  Skeletal cells

10.2.11.  Adipocyte cells

10.3. Middle East and Africa Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

10.3.1. Pharmaceutical

10.3.2. Biotechnology

10.3.3. Cosmetics

10.3.4. Academia

10.4. Middle East and Africa Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. GCC Countries

10.4.1.1.  GCC Countries Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

10.4.1.1.1.  Blood (peripheral) cells

10.4.1.1.2.  Endothelial cells

10.4.1.1.3.  Epithelial cells

10.4.1.1.4.  Fibroblast cells

10.4.1.1.5.  Hepatocyte cells

10.4.1.1.6.  Keratinocyte cells

10.4.1.1.7.  Melanocyte cells

10.4.1.1.8.  Pancreatic cells

10.4.1.1.9.  Smooth muscle cells

10.4.1.1.10.  Skeletal cells

10.4.1.1.11.  Adipocyte cells

10.4.1.2.  GCC Countries Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

10.4.1.2.1.  Pharmaceutical

10.4.1.2.2.  Biotechnology

10.4.1.2.3.  Cosmetics

10.4.1.2.4.  Academia

10.4.2. Southern Africa

10.4.2.1.  Southern Africa Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

10.4.2.1.1.  Blood (peripheral) cells

10.4.2.1.2.  Endothelial cells

10.4.2.1.3.  Epithelial cells

10.4.2.1.4.  Fibroblast cells

10.4.2.1.5.  Hepatocyte cells

10.4.2.1.6.  Keratinocyte cells

10.4.2.1.7.  Melanocyte cells

10.4.2.1.8.  Pancreatic cells

10.4.2.1.9.  Smooth muscle cells

10.4.2.1.10.  Skeletal cells

10.4.2.1.11.  Adipocyte cells

10.4.2.2.  Southern Africa Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

10.4.2.2.1.  Pharmaceutical

10.4.2.2.2.  Biotechnology

10.4.2.2.3.  Cosmetics

10.4.2.2.4.  Academia

10.4.3. Rest of MEA

10.4.3.1.  Rest of MEA Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

10.4.3.1.1.  Blood (peripheral) cells

10.4.3.1.2.  Endothelial cells

10.4.3.1.3.  Epithelial cells

10.4.3.1.4.  Fibroblast cells

10.4.3.1.5.  Hepatocyte cells

10.4.3.1.6.  Keratinocyte cells

10.4.3.1.7.  Melanocyte cells

10.4.3.1.8.  Pancreatic cells

10.4.3.1.9.  Smooth muscle cells

10.4.3.1.10.  Skeletal cells

10.4.3.1.11.  Adipocyte cells

10.4.3.2.  Rest of MEA Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

10.4.3.2.1.  Pharmaceutical

10.4.3.2.2.  Biotechnology

10.4.3.2.3.  Cosmetics

10.4.3.2.4.  Academia

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Type

10.5.3. By Application

11. Latin America Human Primary Cell Market Analysis and Forecasts, 2018 – 2026

11.1. Overview

11.1.1. Latin America Human Primary Cell Market Revenue (US$ Mn)

11.2. Latin America Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

11.2.1. Blood (peripheral) cells

11.2.2. Endothelial cells

11.2.3. Epithelial cells

11.2.4. Fibroblast cells

11.2.5. Hepatocyte cells

11.2.6. Keratinocyte cells

11.2.7. Melanocyte cells

11.2.8. Pancreatic cells

11.2.9. Smooth muscle cells

11.2.10.  Skeletal cells

11.2.11.  Adipocyte cells

11.3. Latin America Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

11.3.1. Pharmaceutical

11.3.2. Biotechnology

11.3.3. Cosmetics

11.3.4. Academia

11.4. Latin America Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. Brazil

11.4.1.1.  Brazil Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

11.4.1.1.1.  Blood (peripheral) cells

11.4.1.1.2.  Endothelial cells

11.4.1.1.3.  Epithelial cells

11.4.1.1.4.  Fibroblast cells

11.4.1.1.5.  Hepatocyte cells

11.4.1.1.6.  Keratinocyte cells

11.4.1.1.7.  Melanocyte cells

11.4.1.1.8.  Pancreatic cells

11.4.1.1.9.  Smooth muscle cells

11.4.1.1.10.  Skeletal cells

11.4.1.1.11.  Adipocyte cells

11.4.1.2.  Brazil Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

11.4.1.2.1.  Pharmaceutical

11.4.1.2.2.  Biotechnology

11.4.1.2.3.  Cosmetics

11.4.1.2.4.  Academia

11.4.2. Rest of Latin America

11.4.2.1.  Rest of Latin America Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Type

11.4.2.1.1.  Blood (peripheral) cells

11.4.2.1.2.  Endothelial cells

11.4.2.1.3.  Epithelial cells

11.4.2.1.4.  Fibroblast cells

11.4.2.1.5.  Hepatocyte cells

11.4.2.1.6.  Keratinocyte cells

11.4.2.1.7.  Melanocyte cells

11.4.2.1.8.  Pancreatic cells

11.4.2.1.9.  Smooth muscle cells

11.4.2.1.10.  Skeletal cells

11.4.2.1.11.  Adipocyte cells

11.4.2.2.  Rest of Latin America Human Primary Cell Market Revenue (US$ Mn) and Forecasts, By Application

11.4.2.2.1.  Pharmaceutical

11.4.2.2.2.  Biotechnology

11.4.2.2.3.  Cosmetics

11.4.2.2.4.  Academia

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Type

11.5.3. By Application

12. Competitive Benchmarking

12.1. Player Positioning Analysis

12.2. Global Presence and Growth Strategies

13. Player Profiles

13.1. Cell Biologics

13.1.1. Company Details

13.1.2. Company Overview

13.1.3. Product Offerings

13.1.4. Key Developments

13.1.5. Financial Analysis

13.1.6. SWOT Analysis

13.1.7. Business Strategies

13.2. Cureline

13.2.1. Company Details

13.2.2. Company Overview

13.2.3. Product Offerings

13.2.4. Key Developments

13.2.5. Financial Analysis

13.2.6. SWOT Analysis

13.2.7. Business Strategies

13.3. Lonza

13.3.1. Company Details

13.3.2. Company Overview

13.3.3. Product Offerings

13.3.4. Key Developments

13.3.5. Financial Analysis

13.3.6. SWOT Analysis

13.3.7. Business Strategies

13.4. Pelobiotech 

13.4.1. Company Details

13.4.2. Company Overview

13.4.3. Product Offerings

13.4.4. Key Developments

13.4.5. Financial Analysis

13.4.6. SWOT Analysis

13.4.7. Business Strategies

13.5. PromoCell GmbH

13.5.1. Company Details

13.5.2. Company Overview

13.5.3. Product Offerings

13.5.4. Key Developments

13.5.5. Financial Analysis

13.5.6. SWOT Analysis

13.5.7. Business Strategies

13.6. Sigma-Aldrich

13.6.1. Company Details

13.6.2. Company Overview

13.6.3. Product Offerings

13.6.4. Key Developments

13.6.5. Financial Analysis

13.6.6. SWOT Analysis

13.6.7. Business Strategies

13.7. Stemcell Technologies

13.7.1. Company Details

13.7.2. Company Overview

13.7.3. Product Offerings

13.7.4. Key Developments

13.7.5. Financial Analysis

13.7.6. SWOT Analysis

13.7.7. Business Strategies

13.8. Thermo Fisher Scientific

13.8.1. Company Details

13.8.2. Company Overview

13.8.3. Product Offerings

13.8.4. Key Developments

13.8.5. Financial Analysis

13.8.6. SWOT Analysis

13.8.7. Business Strategies

13.9. Zen-Bio

13.9.1. Company Details

13.9.2. Company Overview

13.9.3. Product Offerings

13.9.4. Key Developments

13.9.5. Financial Analysis

13.9.6. SWOT Analysis

13.9.7. Business Strategies

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com